Categories: विज्ञान

AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports

(Reuters) -AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday. The agreement with Algen gives AstraZeneca exclusive rights to develop and commercialise therapies from the Crispr gene-editing technology, the report said. Reuters could not immediately confirm the FT report. (Reporting by Raechel Thankam Job in Bengaluru; Editing by Rashmi Aich)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

Inkhabar webdesk

Share
Published by Inkhabar webdesk

Recent Posts

U2 release new arena-ready single and announce a studio album

London (dpa) - Stadium-hopping rock giants U2 have dropped a new radio-ready single and accompanying…

11 minutes ago

Most Rolling Stones are in their 80s, but this album doesn't show it

On their new album "Foreign Tongues", the Rolling Stones are brimming with energy and a…

4 hours ago

When your therapist is an alpaca: How helpful are animals in therapy?

Stroking a dog or riding a horse can release oxytocin and ease stress and anxiety.…

7 hours ago

'Jesus Christ Superstar' returns to rock roots with West End revival

By Hanna Rantala LONDON, July 7 (Reuters) - Rock musical "Jesus Christ Superstar" returns to…

8 hours ago

Oregon to ask court to delay Paramount deal for 60 days while it reviews records

By Jody Godoy July 7 (Reuters) - The Oregon attorney general will ask a court…

9 hours ago

'Jesus Christ Superstar' returns to rock roots with West End revival

By Hanna Rantala LONDON, July 7 (Reuters) - Rock musical "Jesus Christ Superstar" returns to…

9 hours ago